Researchers determined no convincing associations existed between obesity and the risk for malignant melanoma, according to study results published in a letter to the editor of the Journal of Investigative Dermatology.
MRV Research
COMBI-v affirms combination MEK, BRAF blockade in melanoma
More complete blockade of the MAP kinase pathway with both a BRAF and MEK inhibitor decreased the risk of death by one-third among patients with advanced BRAF mutation–positive melanoma in the phase III COMBI-v study.
Scientists Discover New Melanoma Cell Subpopulation To Blame For Drug-Resistant Tumors
Just when researchers thought they knew all there was to know about melanoma cells, they have found new characteristics of these cancer cells. A new breed of melanoma cells was recently discovered, and they behave exactly like non-cancerous endothelial cells that populate blood vessels in tumors. Targeting these cells may be another cancer management therapy that scientists think they can exploit.
Lion Biotechnologies CSO Laszlo Radvanyi Co-Authors Study in Journal of Immunotherapy
Lion Biotechnologies, Inc. , a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TILs), today announced that research by chief scientific officer Laszlo Radvanyi, PhD, has been published in the current issue of Journal of Immunotherapy.